
Thursday, November 29, 2018 1:48:09 PM
The biggest mistake novice biotech investors make is falling in love with a novel product that will be hard to sell and/or is going to be difficult for the FDA to approve it, so it burns huge money for years while the company fights with the hospital buyers after a prolonged fight with the ivory tower theorists at the FDA.
VMS is not novel at all and selling will be relatively easy because it is somewhat of a plug and play addition to hospitals existing ultrasound.
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00022463
Recent VPTDF News
- Shares Of AI Company Surging On FDA 510(k) Clearance News • AllPennyStocks.com • 02/27/2025 05:55:00 PM
- News Brief: Ventripoint Diagnostics Ltd. • AllPennyStocks.com • 11/20/2024 02:10:00 AM
- Will Shares Rise on Milestone Development for AI-Powered Heart Technology? • AllPennyStocks.com • 05/06/2024 01:50:00 PM
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM
UAV Corp Names David Dugas as President and Chief Operating Officer • UMAV • Apr 17, 2025 8:30 AM
Yuengling's Ice Cream Corporation (OTC: YCRM), Doing Business as ReachOut, Files 2024 10-K With Profitability, Growth, and Corporate Transformation in Focus • YCRM • Apr 16, 2025 11:07 AM
Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit • AVAI • Apr 16, 2025 8:00 AM
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers • HLYK • Apr 14, 2025 8:00 AM
Glidelogic Corp. Partners with Sunwah Global Youth Innovation Center • GDLG • Apr 10, 2025 4:00 PM